ArticleAmerican journal of translational research2019
LncRNA PCAT6 increased cholangiocarcinoma cell proliferation and invasion via modulating miR-330-5p.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- LINC00519 promotes the progression of cholangiocarcinoma through regulating the axis of miR-876-3p/GATA1.Discover oncology · 2025Article
- LncRNA PCAT6 mediates UBFD1 expression via sponging miR-545-3p in breast cancer cells.Non-coding RNA research · 2024Article
- Circulating tumor cell-derived exosome-transmitted long non-coding RNA TTN-AS1 can promote the proliferation and migration of cholangiocarcinoma cells.Journal of nanobiotechnology · 2024Article
- Non-coding RNA and Drug resistance in cholangiocarcinoma.Non-coding RNA research · 2024Review
- LncRNA PCAT6 is a predictor of poor prognosis of colorectal cancer.Journal of gastrointestinal oncology · 2024Article
- lncRNA TMPO antisense RNA 1 promotes the malignancy of cholangiocarcinoma cells by regulating let-7g-5p/ high-mobility group A1 axis.Bioengineered · 2022Article
- Review
- PCAT6 may be a new prognostic biomarker in various cancers: a meta-analysis and bioinformatics analysis.Cancer cell international · 2021Review
- Suppression of circulatingOncology letters · 2021Article
- mClinical and translational medicine · 2021Article
- LncRNA PCAT6 regulates the progression of pituitary adenomas by regulating the miR-139-3p/BRD4 axis.Cancer cell international · 2021Article
- The Role of lncRNA PCAT6 in Cancers.Frontiers in oncology · 2021Review
- Assessing the Regulatory Functions of LncRNA SNHG11 in Gastric Cancer Cell Proliferation and Migration.Frontiers in cell and developmental biology · 2021Article
- A Novel Pyroptosis-Associated Long Noncoding RNA Signature to Predict the Prognosis of Patients with Colorectal Cancer.International journal of general medicine · 2021Article
- Long non‑coding RNA PCAT6 promotes the development of osteosarcoma by increasing MDM2 expression.Oncology reports · 2020Article
- LncRNA SNHG11 Promotes Proliferation, Migration, Apoptosis, and Autophagy by Regulating hsa-miR-184/AGO2 in HCC.OncoTargets and therapy · 2020Article
- Long Non-Coding RNA PCAT6 Induces M2 Polarization of Macrophages in CholangiocarcinomaFrontiers in oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) act important roles in several tumors including cholangiocarcinoma. However, the expression pattern and function of PCAT6 in intrahepatic cholangiocarcinoma remains unknown. In our research, we showed that the PCAT6 expression level was upregulated in intrahepatic cholangiocarcinoma cell lines. The expression of PCAT6 in intrahepatic cholangiocarcinoma tissues than that in noncancerous samples and the higer expression of PCAT6 was associated with advanced stage. Ectopic expression of PCAT6 induced cell proliferation and invasion in cholangiocarcinoma cell. Moreover, we demonstrated that PCAT6 interacts with miR-330-5p by directly targeting and PCAT6 overexpression inhibited the expression of miR-330-5p in the ICC-9810 cell. We also showed that the expression level of miR-330-5p in intrahepatic cholangiocarcinoma samples was downregulated compared to noncancerous tissues. Interesting, we proved that the miR-330-5p expression was negative correlated with PCAT6 expression in intrahepatic cholangiocarcinoma. Ectopic expression of miR-330-5p suppressed cell proliferation and invasion. Finally, we showed that PCAT6 induced cell proliferation and invasion by decreasing miR-330-5p in cholangiocarcinoma cell. Taken together, these data suggested that lncRNA PCAT6 was an oncogenic player in the development of intrahepatic cholangiocarcinoma.
Indexed as
Identifiers
31632586PMC6789233W2985195098What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.